Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of GRT6005 for moderate to severe chronic low back pain
NL-OMON39632Phase 2Active, not recruiting
- Sponsor
- Grünenthal GmbH
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cebranopadol in chronic low back pain (CLBP) (5 arms), sponsored by Grünenthal GmbH. Primary endpoints: Change from baseline to weekly average 24-hour pain during the 12-week maintenance phase and Change from baseline to average 24-hour pain during Week 12 of the maintenance phase. Started Jul 2013; status: active, not recruiting.
02
Drugs
cebranopadol
03
Conditions
chronic low back pain (CLBP)
Beyond the preview
Go deeper on NL-OMON39632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39632.